AZD3839 是一种具有口服活性的、选择性的、可透过大脑屏障的BACE1抑制剂 (Ki=26 nM)，对 BACE2 和组织蛋白酶 D 的选择性分别为 14 倍和 >1000 倍。在小鼠、豚鼠和非人灵长类动物中，它剂量和时间依赖性的降低血浆、脑和脑脊液 Aβ 水平，可用于研究阿尔茨海默病。

AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.

In SH-SY5Y cells, AZD3839 efficiently decreases the Aβ40 levels with IC50 of 4.8 nM, and decreases the formation of sAPPβ with IC50 of 16.7 nM. AZD3839 also decreases the Aβ40 levels secreted from C57BL/6 mouse primary cortical neurons, N2A cells, and Dunkin-Hartley guinea pig primary cortical neurons with IC50 values of 50.9, 32.2, and 24.8 nM, respectively. [1] AZD3839 causes in vitro BACE1 inhibition in the cell assay with IC50 value of 16.7 nM. [2]

In C57BL/6 mice, AZD3839 (69 mg/kg, p.o.) causes a dose- and time-dependent reduction of plasma and brain Aβ. In guinea pig and non-human primates, AZD3839 also inhibits Aβ generation. [1]

1227163-84-9

C24H16F3N5

431.422

AZD3839

DMSO:80 mg/mL (185.4 mM)
H2O:<1 mgml
Ethanol:80 mg/mL (185.4 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years